

Ventizolve[®]

1.26 mg nasal naloxone spray

Reversal
of opioid
overdoses in
medical and
non-medical
settings

Product

Naloxone, 1.26 mg nasal spray.
ATC: V03AB15

Therapeutic indication:

Ventizolve is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression, in both non-medical and healthcare settings.

Regulatory Status:

Approved in: Sweden, Norway,
Denmark, Finland, Iceland,
United Kingdom, Ireland, Germany,
France, Italy, The Netherlands,
Belgium and Estonia

Reimbursed in:

Norway and Sweden



Dose chosen to
avoid withdrawal
and abstinence
symptoms

Packaging designed
to fit in a pocket or
a bag

Easy to administer
for lay people

1	Approved for both medical and non medical settings	The persons in risk for experiencing an opioid overdose is not only high risk opioid users, but also users of other illegal drugs that may contain opioids and also users of prescription opioids
2	1.26 mg per dose	When choosing the dose it is important to consider the balance between sufficient effect and avoid unnecessary Withdrawal and abstinence symptoms, as this increases the risk of more opioid intake and experiencing another overdose within short time after the first.
3	Packaging	Opioid overdoses can occur any place at any time, and therefore it is important to always carry your naloxone with you at all times
4	Stigma	Using opioids is related to a lot of stigma from the public. The design is chosen to ensure compliance but avoiding stigma from bystanders

